Pharma: Clinic Roundup

 Bayer HealthCare Pharmaceuticals Inc., a Wayne, N.J.-based subsidiary of Bayer AG, began enrolling patients in an international Phase II/III trial to evaluate BAY94-9027 as a prophylactic and on-demand treatment of hemophilia A.